Download Acute Myocardial Infarction Associated with Pregnancy

Acute Myocardial Infarction Associated with Pregnancy
Arie Roth, MD, and Uri Elkayam, MD
1 November 1996 | Volume 125 Issue 9 | Pages 751-762
Purpose: To review available information on the epidemiology, cause, diagnosis, prognosis, and treatment of acute myocardial
infarction during pregnancy or in the early postpartum period and to develop guidelines for the management of this condition.
Data Sources: MEDLINE and Index Medicus searches and a manual search of bibliographies from reviewed articles.
Study Selection: Published reports of well-documented acute myocardial infarction during pregnancy or the early postpartum
period or potentially relevant information.
Data Extraction: 125 well-documented cases of myocardial infarction were identified.
Data Synthesis: The highest incidence seems to occur in the third trimester and in multigravidas older than 33 years of age.
Acute myocardial infarction during pregnancy is most commonly located in the anterior wall. The maternal death rate was 21%;
death occurred most often at the time of acute myocardial infarction or within 2 weeks of the infarction and was usually related to
labor and delivery. Most fetal deaths were associated with maternal deaths. Coronary artery morphology was studied in 54% of
described patients. Coronary atherosclerosis with or without intracoronary thrombus was found in 43% of patients, coronary
thrombus without atherosclerotic disease in 21%, coronary dissection in 16%, and normal coronary arteries in 29%.
Conclusions: Acute myocardial infarction during pregnancy or the early postpartum period is rare but may be associated with
high risk. Although atherosclerosis can be documented in many cases, coronary dissection and arteries that are normal on
angiography are common, especially in acute myocardial infarction occurring in the peripartum or postpartum period. Early
diagnosis is often hindered by the normal changes of pregnancy and low level of suspicion. Management should follow the usual
principles of care for acute myocardial infarction. However, selection of diagnostic and therapeutic approaches may be greatly
influenced by fetal safety.
Acute myocardial infarction rarely occurs in women of childbearing age and has been estimated to occur in only 1 in 10 000
women during pregnancy [1, 2]. Since the first report in 1922 [3], many additional cases have been published in the literature [4109], indicating the unique features of acute myocardial infarction that can significantly affect maternal and fetal outcomes. With
the current trend of childbearing at an older age and the ongoing effects of cigarette smoking, stress, and cocaine use, the
occurrence of acute myocardial infarction during pregnancy can be expected to increase. We review the clinical aspects of acute
myocardial infarction in the gestational and early postpartum period in 125 well-documented cases and attempt to establish
recommendations for the management of this condition.
Methods
A literature search for acute myocardial infarction during pregnancy was done using MEDLINE and Index Medicus. All original
articles were obtained from the University of Southern California library, interlibrary communications, or the authors of the articles.
Translators were used to translate all original articles written in foreign languages. Only cases of acute myocardial infarction that
were documented by chest pain, standard electrocardiographic criteria, and enzymatic changes (or histologic changes in patients
who died) were selected for review. Six cases that were described as acute myocardial infarction but did not fulfill the
aforementioned criteria were excluded from the analysis.
Epidemiologic data were used to compare selected patients who had acute myocardial infarction in the antepartum (as many as
24 hours before labor), peripartum (within 24 hours before or after delivery), and postpartum (from 24 hours to 3 months after
delivery) periods. We make recommendations on the basis of available information, with the understanding that the 125 cases
identified in our review may not represent all patients who have acute myocardial infarction associated with pregnancy and that
reporting may be biased in favor of unusual cause, presentation course, and outcome.
Epidemiology
Although acute myocardial infarction has occurred in pregnant women at all stages of pregnancy and at ages between 16 and 45
years, this event usually occurs in the third trimester in women older than 33 years (Table 1). Patients who had acute myocardial
infarction in the postpartum period (mean age ±SD, 29 ± 6 years) were substantially younger than women who had acute
myocardial infarction in the antepartum (mean age, 33 ± 6 years) or peripartum (mean age, 34 ± 5 years) period. In addition, acute
myocardial infarction associated with pregnancy has been noted to occur most commonly in multigravidas and is most commonly
located in the anterior wall. Most maternal deaths occurred either at the time of infarction (usually resulting in an undelivered child)
or within 2 weeks of infarction [1] (usually in association with labor and delivery). No association could be found, however, between
maternal death and method of delivery (Table 2). The cumulative reported maternal mortality rate was 21%; rates in the
peripartum or postpartum period were higher than those in the antepartum period. Most fetal deaths (10 of 16 [62%]) were
associated with maternal deaths, and maternal survival was usually accompanied by normal fetal outcome. The remaining fetal
deaths resulted from spontaneous abortion or unexplained stillbirth. Overall, fetal mortality (13%) was lower than maternal
mortality.
When coronary artery morphology was studied (through use of angiography or at autopsy) during pregnancy or shortly thereafter
(54% of reported patients), coronary atherosclerosis with or without intracoronary thrombus was found in 43% of patients (29 of
68) and definite or probable coronary thrombus without evidence of atherosclerotic disease was present in 21% of patients (14 of
68). Atherosclerotic disease was found more commonly in women with acute myocardial infarction in the antepartum period (58%)
than in those with acute myocardial infarction in the peripartum (12%) or postpartum (29%) period. Coronary dissection was found
in 16% of patients (11 of 68) and was the primary cause of infarction in the postpartum period (33%). Normal coronary arteries
were reported in 29% (20 of 68) of all cases and 75% of those with acute myocardial infarction in the peripartum period.
Causes
Risk factors for myocardial infarction in young women generally include a family history of coronary artery disease; familial
hyperlipoproteinemia; low levels of high-density lipoprotein cholesterol, high levels of low-density lipoprotein cholesterol, or both;
diabetes mellitus; cigarette smoking; and previous use of oral contraceptives [110]. Although it seems to be the primary cause of
acute myocardial infarction during pregnancy, atherosclerotic disease was found in less than half of patients in whom coronary
anatomy was investigated (Table 1). Other potential causes include thrombosis, coronary artery spasm (either spontaneous [37] or
induced by bromocriptine mesylate [7, 17]), coronary artery dissection [15, 31, 71], collagen vascular disease [16, 41], Kawasaki
disease [18], cocaine use [24], aortic valvular stenosis, aortic prosthetic valve thrombosis [23], sickle cell chronic lung disease [65],
pheochromocytoma [93], and fibrosis of a coronary ostium secondary to repeated trauma by a papillary fibroelastoma with a long
stalk that was strategically located in front of the ostium [100]. Despite the many potential causes, their rarity during childbearing
age may explain the low rate of acute myocardial infarction during pregnancy.
Twenty-nine percent of patients in whom coronary artery anatomy was defined were found to have normal coronary arteries
(Table 1). Because a thrombus was found without atherosclerotic disease in 21% of the patients, a transient coronary spasm
resulting in acute coronary thrombosis as a result of the hypercoagulable state of pregnancy is a possible explanation. Failure to
identify similar cases of thrombosis in other patients may be related to doing angiography in late stages of pregnancy. Because
acute myocardial infarction has been related to pregnancy-induced hypertension and preeclampsia, enhanced vascular reactivity
to angiotensin II [111] and norepinephrine [112] and endothelial dysfunction [113] [which have been reported in these conditions]
may also promote coronary constriction. Other suggested causes of coronary spasm are 1) decreased uterine perfusion in the
supine position leading to renin release and angiotensin production [32] and 2) ergot derivatives that are used to control
postpartum [33] or postabortion [21] hemorrhage or to suppress lactation [7, 13, 14].
The profound alterations in the coagulation and fibrinolytic system that occur during pregnancy increase the risk for thrombosis.
These alterations include decreased releasable tissue plasminogen activator (t-PA) [114-116], increased fast-acting t-PA inhibitor
[116, 117], change in the level of coagulation factors [115, 118], and reduction in functional protein S levels [26, 119, 120].
Cigarette smoking during pregnancy further increases risk for thrombosis because of enhanced platelet aggregability [121].
Hypercoagulation is further augmented at the time of separation of the placenta, which is a major source of t-PA inhibitor [119].
Coronary arterial dissections related to pregnancy have been reported to occur in the antepartum and postpartum periods, but
most cases seem to occur in the immediate postpartum period Table 1 [122, 123]. It has been suggested [15] that
angiographically normal coronary arteries seen in many patients who had acute myocardial infarction in the peripartum period may
represent healed or spontaneously repaired coronary dissections. The cause for dissection may be hormonally mediated
biochemical and histologic changes that have been reported to occur in arterial walls during gestation, such as loss of normal
corrugation in elastic fibers, fragmentation of reticular fibers, and decrease in the content of acid mucopolysaccharide [124, 125].
The marked increases in blood volume, stroke volume, and heart rate that are usually seen during pregnancy [126] can increase
myocardial oxygen demand. At the same time, the physiologic anemia and decreased diastolic blood pressure that occur during
gestation may reduce myocardial oxygen supply and contribute to the development of myocardial ischemia when coronary blood
supply is compromised. Anxiety, pain, and uterine contraction may further augment these ischemic events during labor and
delivery and may be associated with as much as a threefold increase in oxygen consumption. In the puerperium, increased
hemodynamic load may be further increased by enhanced return of venous blood to the heart with relief of caval compression and
shift of blood from the contracting emptied uterus into the systemic circulation. The hemodynamic changes that normally occur
during late pregnancy and during labor, delivery, and the puerperium [126] may contribute to poor outcome in women who have an
acute myocardial infarction in the peripartum period.
Diagnosis and Clinical Considerations
Early diagnosis of acute myocardial infarction during pregnancy is often hindered by mistaking its signs and symptoms for normal
manifestations of pregnancy [127] and because of a low level of suspicion. Diagnosis in pregnant women is confirmed as it is in
nonpregnant patients, primarily by electrocardiographic and changes in enzyme levels. Therefore, it is important to note that
electrocardiographic changes that mimic myocardial ischemia have been reported in as many as 37% of parturients having
elective cesarean section [128, 129]. Echocardiography can be done safely during pregnancy to confirm the presence of ischemia
by showing wall motion abnormalities that correspond to electrocardiographic changes. Although myocardial ischemia is often
associated with cardiac arrhythmias [8], this association is less helpful to diagnosis in pregnant women when various arrhythmias
(especially those characterized by multiple atrial and ventricular premature beats but also supraventricular and ventricular
tachycardia) occur in women with normal hearts [130, 131].
The use of radiation during pregnancy should generally be kept to a minimum. The amount of fetal exposure to radiation during
chest radiography is extremely small and should probably be considered safe and used when appropriate [132]. Radionuclide
ventriculography using technetium 99m and myocardial perfusion scanning using thallium-201 or technetium 99m sestamibi is
expected to yield less than 0.01 Gy to the conceptus but should be used during pregnancy only when absolutely necessary.
Cardiac catheterization and interventional procedures may also result in fetal exposure to less than 0.01 Gy. However, difficult
procedures requiring longer fluoroscopy time and several cine views could easily yield a fetal radiation exposure of 0.05 to 0.10
Gy. Termination of pregnancy is not generally recommended for fetal doses of radiation less than 0.05 Gy but may be considered
when the dose exceeds that amount.
Treatment
Although the management of acute myocardial infarction and its complications should follow the usual principles of care, fetal
considerations may affect the choice of therapy. Close consultation among the attending obstetrician, internist or cardiologist, and
anesthesiologist is essential to optimize maternal and fetal well-being. Ideally, the patient should be treated in an intensive care
unit that is capable of providing maternal and fetal monitoring along with a comprehensive obstetric service. A plan for prompt
rescue of a potentially viable fetus in the case of sudden maternal deterioration should be established.
Morphine Sulfate
This drug has not caused congenital defects, but because it crosses the placenta, it may cause neonatal respiratory depression
when given shortly before delivery [133]. Morphine enters breast milk only in trace amounts and is considered compatible with
breast-feeding [134].
Thrombolytic Therapy
Thrombolytic therapy is a first-line treatment of acute myocardial infarction but has had limited use in pregnancy [135-148]. In fact,
pregnancy currently constitutes a contraindication for thrombolytic treatment [66, 94], although the basis for such prohibition is
strictly theoretical and has probably been adopted from research protocols in which pregnancy was an exclusion criterion.
Streptokinase and t-PA do not cross the placenta in animals. However, no information is available on the passage of streptokinase
in the human placenta during early pregnancy; streptokinase has not been shown to cross the placenta in late pregnancy and has
only minimal placental passage during labor [135, 139]. On the other hand, streptokinase antibodies were detected in neonatal
spinal cord blood after women received streptokinase several weeks before delivery [137]. Urokinase was not found to be
teratogenic in rats or mice [149]. Clinical experience with use of thrombolytic therapy during pregnancy has been mostly with
streptokinase, and this experience has been reported primarily in patients with massive and hemodynamically significant
pulmonary embolism [136, 142, 145, 146], deep venous thrombosis [137], or prosthetic valve thrombosis [138, 143, 144, 148,
150]. Because thrombolytic therapy has played a pivotal role in modern treatment of acute myocardial infarction, the reported
experience with this therapy during pregnancy is shown in Table 3.
Available reports describe the use of therapeutic doses of streptokinase [137, 141-144], t-PA [145-147], and urokinase [42, 136,
138, 145] between the 9th and 38th week of gestation [147]. Delivery occurred during thrombolytic therapy or 1 to 2 days after
therapy was stopped in several cases [141, 142, 145-147]. Although maternal and fetal outcomes were normal in some reports,
documented complications include maternal hemorrhage, preterm delivery, and fetal loss [135, 137, 141, 142]. Hemorrhagic
complications included spontaneous abortion, minor vaginal bleeding that did not require intervention [135, 138], spontaneous
hematoma in the inguinal and axillary region that required blood transfusion [135], fatal abruptio placentae with fetal death [137],
uterine bleeding that required emergency cesarean section [137, 148], and postpartum hemorrhage that required transfusion [141,
142]. The risk for hemorrhagic complications seems to increase when thrombolytic therapy is given at the time of delivery. Fetal
hemorrhage or teratogenic effects have not been reported, and fetal outcome has been favorable in most reported cases.
Thrombolytic therapy was used during the first trimester in seven cases [135], and fetal loss occurred in one case. Most reported
cases of fetal loss in patients receiving thrombolytic therapy do not seem to be related to treatment. In one case, however, fetal
death was caused by abruptio placentae during therapy [137]. In another case, fetal heartbeat stopped during thrombolytic
therapy, and a treatment-related cause could not be ruled out [150]. In addition, intracranial hemorrhages were reported in a
newborn infant whose mother had received t-PA during pregnancy; the infant died of the acute distress syndrome 14 days after
delivery [146].
In summary, the few available reports on the use of thrombolytic therapy during pregnancy do not support a teratogenic effect.
Although most reported cases were associated with favorable maternal and fetal outcomes, therapy is associated with a risk for
maternal hemorrhage, especially when thrombolytic agents are given at the time of delivery. The occasional fetal loss that was
reported did not seem to be related to therapy in most instances, although such a relation could not always be ruled out. More
information is needed before fetal safety during thrombolytic therapy can be established.
Anticoagulation Therapy
Because of its large molecular size, heparin does not cross the placenta, is not teratogenic, and is therefore the anticoagulant of
choice during pregnancy [151]. Because its effect may persist for as long as 28 hours, discontinuation of therapy 24 hours before
elective induction of labor is desirable [151]. Heparin therapy should be discontinued with the onset of spontaneous labor, and
judicious use of protamine sulfate may be needed to reduce the risk for bleeding and to allow safe pudendal and epidural
anesthesia [151, 152]. Hemostatic stitches should be used to prevent bleeding caused by episiotomy; uterine contraction should
be stimulated by massage after delivery; and oxytocin or ergot derivatives should be used to stop bleeding. Heparin therapy can
be resumed after delivery as soon as hemostasis seems adequate. Heparin is not secreted in breast milk [134].
Aspirin
The safety of high doses of aspirin during pregnancy is debatable, especially during the third trimester. At this time, high doses
may lead to increased maternal and fetal hemorrhage, congenital abnormalities, and premature closure of the ductus arteriosus
[153, 154]. On the other hand, the safety of low dosages of aspirin (
150 mg/d), which effectively inhibit thromboxane
synthesis [155], has been shown during the second and third trimester in many hypertensive pregnant women [156]. The safety of
aspirin during the first trimester is still unclear [151]. Although aspirin is secreted in breast milk in low concentrations, cautious use
of aspirin by lactating women has been recommended and adverse effects have not been reported [134].
Organic Nitrates
Intravenous or oral nitrates have been used during pregnancy to treat hypertension [157], myocardial ischemia [66], and infarction
[158] and to arrest preterm labor [159]. No known adverse effects of nitrate therapy during pregnancy have been seen; however,
careful titration is recommended to avoid maternal hypotension, which can lead to fetal distress [157]. No data are available on
breast-feeding in women treated with these drugs.
ß-Adrenergic Blocking Agents
Substantial experience with the use of propranolol, atenolol, labetalol, and metoprolol in pregnancy suggests that they are safe for
use during gestation [160], although such side effects as fetal growth retardation, bradycardia, hypoglycemia, hyperbilirubinemia,
and apnea at birth have been anecdotally reported. Because nonselective ß-blockers may facilitate an increase in uterine activity,
use of ß1-selective agents may be preferable. All ß-blockers are weak bases and accumulate in greater concentrations in breast
milk than in plasma. Nursing infants should therefore be monitored for adverse effects [160].
Calcium Antagonists
Increasing experience with use of nifedipine during gestation for treatment of hypertension, preeclampsia, myocardial ischemia,
and tocolysis has shown the safety of this drug [161]. Information about the use of verapamil and diltiazem during pregnancy is
more limited [162]. A recent surveillance study [163] suggested that diltiazem may have teratogenic effects. Nifedipine, verapamil,
and diltiazem are all considered to be compatible with breast-feeding [134].
Magnesium Sulfate
Although it is still debated whether magnesium sulfate should be used routinely in pregnant patients who have had acute
myocardial infarction, early administration of the drug to high-risk patients (especially those who do not receive thrombolytic
therapy) has been shown to be useful [164]. Magnesium sulfate is commonly used in pregnancy as a tocolytic agent and as an
anticonvulsant agent for toxemia. Wide clinical experience with this drug during pregnancy has not shown teratogenic effects or
other forms of toxicity [134, 165]. It should be noted, however, that magnesium sulfate has rarely been used during the first
trimester. Newborn infants of mothers treated with magnesium sulfate close to delivery should be observed for signs of respiratory
depression, muscle weakness, and loss of reflexes, all of which were reported in a hypertensive woman treated with 11 g of
magnesium sulfate within 3.5 hours of delivery [166]. Maternal hypothermia with maternal and fetal bradycardia caused by
intravenous magnesium sulfate use has been described. In addition, hypotension and pronounced muscle weakness have been
reported when the drug was used in combination with nifedipine [165]. Magnesium sulfate is considered to be compatible with
breast-feeding [134].
Complications
Congestive Heart Failure
Diuretics should be used cautiously to prevent diuresis of too great an extent, hypovolemia, and subsequent reduction in
uteroplacental blood flow [167]. Nitrates are effective, but careful dose titration is recommended to avoid reducing blood pressure.
Sodium nitroprusside has been used in some patients during pregnancy, but its safety is unknown [167]. A large dose of sodium
nitroprusside resulted in fetal death in animals, showing a potential for fetotoxicity. Dopamine has had only limited use in pregnant
humans. Studies in animals have shown both an increase and a decrease in uterine blood flow [168, 169]. The drug has been
used to increase renal blood flow in oliguric, eclamptic patients and to treat spinal anesthesia-related hypotension during cesarean
section without apparent adverse effects to the fetus or newborn infant [168-170]. Information about the use of dobutamine during
pregnancy is similarly limited. Short-term use of this drug in one patient with myocardial infarction at 18 weeks gestation and in a
patient with pulmonary hypertension before delivery was not associated with adverse effects [6, 171]. Angiotensin-converting
enzyme inhibitors are contraindicated during pregnancy because of increased incidence of fetal illness and death [172]. Reported
complications include oligohydramnios, intrauterine growth retardation, premature labor, fetal and neonatal renal failure, bone
malformations, limb contractures, persistent patent ductus arteriosus, pulmonary hypoplasia, the respiratory distress syndrome,
prolonged hypotension, and neonatal death. If heart failure persists or the clinical condition of the patient deteriorates, more
aggressive approaches should be pursued. In one case of severe hemodynamic instability, treatment with intra-aortic balloon
counterpulsation was successful and allowed postponement of delivery until hemodynamic stability could be achieved [20].
Cardiogenic shock accompanying acute myocardial infarction was reported to improve dramatically after cesarean section [11].
Arrhythmias
Drug Therapy
On the basis of substantial clinical experience, use of digoxin and quinidine during gestation is considered to be safe for the fetus
[162]. Procainamide and disopyramide have been successfully used to treat maternal and fetal arrhythmias, but experience with
these drugs is limited. Lidocaine has been used safely during pregnancy mainly for epidural or local anesthesia; it can also be
used as an antiarrhythmic agent as long as blood levels are closely monitored. Elevated levels can cause apnea, hypotonia,
dilated pupils, seizures, and bradycardia in infants [162]. Relatively few pregnant women have been treated with newer
antiarrhythmic agents, such as mexiletine [173], flecainide [174], propafenone, and sotalol [175]. Because information is limited,
the safety of these drugs is unknown. Use of amiodarone during pregnancy has been associated with significant side effects,
including hypothyroidism and congenital malformations in the newborn infant [176]. The drug should therefore be used only in
refractory cases of maternal tachyarrhythmias. A recent survey identified 34 women who received intravenous adenosine during
pregnancy to treat maternal supraventricular arrhythmia [177] and showed the efficacy and safety of adenosine use during
pregnancy.
Cardiac Pacing
Indications for cardiac pacing in pregnant patients who have had acute myocardial infarction are similar to those used for
nonpregnant patients. On the basis of reported experience in many pregnant patients, no problems are anticipated with the use of
temporary pacemakers [178]. These devices, however, should be inserted without fluoroscopy when possible. The recent
introduction of external transcutaneous pacing [179] provides clinicians with an ideal alternative for cardiac pacing during
pregnancy.
Direct-Current Cardioversion
Cardioversion is recommended for treatment of maternal tachyarrhythmias associated with systemic hypotension or heart failure.
Several investigators [1, 4-68, 34] have documented the safety and efficacy of cardioversion and defibrillation in the setting of
myocardial infarction during pregnancy. If possible, monitoring of fetal heart rate is advisable whenever maternal cardioversion is
done.
Postinfarction Angina
If postinfarction angina pectoris is poorly controlled with maximal medical therapy in the early stages of pregnancy (
20
weeks), consideration should be given to termination of the pregnancy. The approach to this condition after the 20th week should
be similar to that in nonpregnant patients. Cardiac catheterization and angiography, if indicated, should be done with fetal
shielding using the brachial or radial approach to reduce scattered radiation to the fetus. Although experience with percutaneous
transluminal coronary angioplasty or coronary artery bypass grafting is limited, these procedures have been done successfully
during pregnancy or the early postpartum period [12, 17, 25, 180]. However, these forms of therapy should be avoided in
pregnancy if possible, especially during the first trimester, because of the potential deleterious effects on the fetus of both radiation
and cardiopulmonary bypass [181].
Cardiopulmonary Resuscitation
Before the onset of fetal viability (at about the 24th week of gestation), the objectives of cardiopulmonary resuscitation can be
guided almost exclusively by maternal considerations; later, consideration should also be given to fetal safety. Success of
cardiopulmonary resuscitation in pregnancy may be hampered by several factors. The thorax is less compressible to external
pressure because of cephalad displacement of abdominal contents. Chest compressions in the supine position may fail to produce
sufficient cardiac output because of reduced venous return and increased obstruction to arterial forward flow. Because of the
elevated diaphragm, resistance to airflow during artificial respiration and to thoracic compressions is increased, making
resuscitation efforts even more difficult [182].
Because of increased oxygen consumption and increased carbon dioxide and hydrogen ion production by fetoplacental
metabolism, any delay in establishing effective ventilation magnifies circulatory compromise of the uteroplacental unit and may
inhibit resuscitation efforts despite adequate chest compression [183]. To minimize the effects of the gravid uterus on venous
return and cardiac output, a wedge (such as a pillow) should be placed under the flank of the right abdomen and hip to displace
the uterus to the left side. If having the mother in the left lateral decubitus position makes resuscitative efforts clumsy and
ineffective, continuous manual displacement to the left or positioning the back of the resuscitated patient on the thighs of a person
kneeling on the floor and sitting back on their heels (the so-called human wedge maneuver) [184] may be used as alternative
methods. To date, no studies comparing closed- and open-chest cardiac massage on the hemodynamics of the human uterus and
placenta have been done. The uteroplacental circulation, however, offers minimal vascular resistance as long as oxygenation and
acid-base balance are not profoundly distorted. Favorable outcomes reported in some cases [185] suggest that the pressure
gradients generated even by standard cardiopulmonary resuscitation may be adequate to sustain fetal life and should be
attempted. At the same time, early evacuation of the uterus by bedside cesarean section resulted in recovery of blood pressure in
a patient who did not generate adequate blood pressure despite vigorous resuscitative measures. Lee and colleagues [186]
recommended thoracotomy and open-chest cardiac massage between the 24th and 32nd week of gestation. Cesarean section
after the 32nd week should be considered if standard cardiopulmonary resuscitation is ineffective.
Survival of the infant has been directly proportional to the time interval between the death of the mother and delivery [187].
Delivery taking place more than 15 minutes after maternal death rarely produces a viable infant, and almost all surviving infants
had some neurologic sequelae. On the other hand, all surviving infants delivered within 5 minutes after maternal death were
healthy. Successful rescue and long-term maintenance of brain-dead and comatose mothers have been accomplished, allowing
for delivery at a time that was more beneficial to the fetus [187, 188]. To maximize the chances of survival for both the mother and
infant [183-190], rapid cesarean section (within 4 to 5 minutes of cardiac arrest) has been recommended.
Several issues about the use of drugs that are commonly administered during resuscitation should be addressed. Routine
administration of bicarbonate has been discouraged in nonpregnant patients during resuscitation because combined respiratory
and metabolic alkalosis caused by vigorous ventilation and bicarbonate administration may be deleterious. During resuscitation of
a pregnant woman, however, the rate of acid metabolite production increases. Because acidosis increases the
-adrenergic
reactivity of the uteroplacental vasculature, use of bicarbonate during resuscitation of a pregnant patient seems logical. Although
-agonists do not cause any hemodynamic derangement in the uteroplacental blood flow
ß-agonists or combined ß- and
during normal pregnancy, hypoxemia or hypotension enhances sensitivity to the vasoconstrictor action of epinephrine and
norepinephrine [191] and thus may further impair uteroplacental flow. For this reason, reduced uteroplacental blood flow due to
hypotension may not improve with vasopressors.
Labor
To allow adequate healing of the infarction, delivery should be postponed, if possible, for 2 to 3 weeks after acute myocardial
infarction. Because of the increased hemodynamic requirements during labor and uterine contractions [126], myocardial ischemia
and cardiac decompensation may occur. In addition, reduced oncotic pressure may predispose patients to the development of
pulmonary edema.
The mode of delivery in a pregnant patient with gestational myocardial infarction should be determined by obstetric reasons and
the clinical status of the mother. Both vaginal and cesarean deliveries have advantages and disadvantages. Review of the
outcomes for all 125 cases in this paper supports the conclusion reached by Cohen and colleagues [4], who found no convincing
support for one method of delivery over the other, and suggests that an individual approach be used. Advantages of elective
cesarean section include control of the time of delivery and avoidance of long or stressful labor. Vaginal delivery, on the other
hand, eliminates the risks associated with anesthesia and a major surgical procedure and avoids potential postoperative morbid
conditions (including hemodynamic fluctuations, blood loss, pain, infection, and respiratory complications) [2, 30]. With measures
aimed to reduce cardiac workload and oxygen demands, vaginal delivery can be accomplished relatively safely [5, 6, 10, 40, 192].
Instrumental delivery is recommended to avoid excessive maternal efforts, and the patient should receive supplemental oxygen.
For optimization of cardiac output, a left lateral position is preferred. Hemodynamic values, as well as oxygen saturation,
electrocardiogram, and fetal heart rate, should be monitored continuously. During labor and delivery, the patient's pain, fear, and
apprehension, all of which can increase myocardial oxygen demand, must be minimized and controlled. Tachycardia and
hypertension should be prevented or, if they occur, promptly corrected. In view of the possibility of coronary spasm, it may be wise
to avoid oxytocin infusion during labor and ergonovine in the postpartum period. Ischemia that develops during labor and delivery
can be treated by intravenous nitroglycerin, ß-blockers, and calcium antagonists. Nitroglycerin, as well as such calcium
antagonists as diltiazem and verapamil, have shown some tocolytic effect and may prolong labor [159, 167].
In summary, selection of the method of delivery for patients after myocardial infarction should be made on an individual basis.
Most patients with coronary artery disease can tolerate vaginal delivery and should therefore have this type of delivery. Cesarean
section is only indicated for obstetric purposes and in patients with unstable ischemic or hemodynamic conditions.
Hospital Discharge
The timing of hospital discharge after acute myocardial infarction needs to be determined on an individual basis. If the pregnancy
has advanced into the third trimester, then continued hospitalization with restricted exertional activities until elective delivery may
be appropriate.
Low-risk patients and patients in earlier stages of pregnancy may be discharged if their clinical condition is stable. Left ventricular
function and presence of residual myocardial ischemia can be assessed using stress echocardiographic study. A recent report [42]
described such an evaluation done 9 days after infarction at 27 weeks of gestation. Because of the potential for fetal distress
during exercise [12], a submaximal exercise protocol and fetal monitoring during exercise are recommended [193]. In cases in
which high-quality echocardiographic evaluation is not possible for technical reasons, thallium exercise testing should be
considered.
Because myocardial oxygen consumption will progressively increase with the progression of pregnancy, close follow-up of the
pregnant patient who has had acute myocardial infarction is recommended after hospital discharge. Assessment of fetal maturity
and reassessment of cardiac status after the 32nd week of gestation are important for determination of management plan and
feasibility of early delivery, if indicated.
Subsequent Pregnancies
Data on maternal and fetal outcome of pregnancy in patients with a history of myocardial infarction are extremely limited [194].
Reported cases of pregnancy after myocardial infarction have not been associated with death but with an increased incidence of
short- and long-term illness [1, 4, 20]. These data must be interpreted with caution because the number of patients was small,
complete obstetric and cardiovascular details were not always presented, and the period between infarction and pregnancy varied
substantially (range, 6 months to 7 years). The risks associated with subsequent pregnancy probably depend on many factors,
including the cumulative amount of myocardial damage, residual left ventricular function, underlying coronary anatomy, and
ongoing myocardial ischemia.
Dr. Elkayam: University of Southern California School of Medicine, Division of Cardiology, 2025 Zonal Avenue, Los Angeles, CA
90033.
Author and Article Information
From the Tel-Aviv Medical Center and Sackler School of Medicine, Tel-Aviv, Israel; and the University of Southern California
School of Medicine, Los Angeles, California.
Requests for Reprints: Uri Elkayam, MD, University of Southern California School of Medicine, Division of Cardiology, 2025
Zonal Avenue, Los Angeles, CA 90033.
Current Author Addresses: Dr. Roth: Department of Cardiology, Ichilov Hospital, 6 Veitzman, Israel.
References
1. Hankins GD, Wendel GD Jr, Leveno KJ, Stoneham J. Myocardial infarction during pregnancy: a review. Obstet Gynecol.
1985; 65:139-46.
2. Sullivan JM, Ramanathan KB. Management of medical problems in pregnancy—severe cardiac disease. N Engl J Med. 1985;
313:304-9.
3. Katz H. About the sudden natural death in pregnancy. During delivery and the puerperium. Archiv Fur Gynaekologie. 1922;
115:283-312.
4. Cohen WR, Steinman T, Patsner B, Snyder D, Satwicz P, Monroy P. Acute myocardial infarction in a pregnant woman at
term. JAMA. 1983; 250:2179-81.
5. Cortis BS, Lee SS, Bacalla M. Acute myocardial infarction and ventricular fibrillation during pregnancy. IMJ III Med J. 1981;
160:170-1, 174.
6. Stokes IM, Evans J, Stone M. Myocardial infarction and cardiac arrest in the second trimester followed by assisted vaginal
delivery under epidural analgesia at 38 weeks gestation. Case report. Br J Obstet Gynaecol. 1984; 91:197-8.
7. Iffy L, TenHove W, Frisoli G. Acute myocardial infarction in the puerperium in patients receiving bromocriptine. Am J Obstet
Gynecol. 1986; 155:371-2.
8. O'Donnell M, Meecham J, Tosson SR, Ward S. Ventricular fibrillation and reinfarction in pregnancy. Postgrad Med J. 1987;
63:1095-6.
9. Dawson PJ, Ross AW. Pre-eclampsia in a parturient with a history of myocardial infarction. A case report and literature review.
Anaesthesia. 1988; 43:659-63.
10. Trouton TG, Sidhu H, Adgey AA. Myocardial infarction in pregnancy. Int J Cardiol. 1988; 18:35-9.
11. Mabie WC, Anderson GD, Addington MB, Reed CM Jr, Peeden PZ, Sibai BM. The benefit of cesarean section in acute
myocardial infarction complicated by premature labor. Obstet Gynecol. 1988; 71(3 Pt 2):503-6.
12. Cowan NC, de Belder MA, Rothman MT. Coronary angioplasty in pregnancy. Br Heart J. 1988; 59:588-92.
13. Sonel A, Erol C, Oral D, Omurlu K, Akyol T, Kaymakcalan S. Acute myocardial infarction and normal coronary arteries in a
pregnant woman. Cardiology. 1988; 75:218-20.
14. Ruch A, Duhring JL. Postpartum myocardial infarction in a patient receiving bromocriptine. Obstet Gynecol. 1989; 74(3 Pt
2):448-51.
15. Movesesian MA, Wray RB. Postpartum myocardial infarction. Br Heart J. 1989; 62:154-6.
16. Rallings P, Exner T, Abraham R. Coronary artery vasculitis and myocardial infarction associated with antiphospholipid
antibodies in a pregnant woman. Aust N Z J Med. 1989; 19:347-50.
17. Giudici MC, Artis AK, Webel RR, Alpert MA. Postpartum myocardial infarction treated with percutaneous transluminal
coronary angioplasty. Am Heart J. 1989; 118:614-6.
18. Nolan TE, Savage RW. Peripartum myocardial infarction from presumed Kawasaki's disease. South Med J. 1990; 83:1360-1.
19. Hands ME, Johnson MD, Saltzman DH, Rutherford JD. The cardiac, obstetric, and anesthetic management of pregnancy
complicated by acute myocardial infarction. J Clin Anesth. 1990; 2:258-68.
20. Allen JN, Wewers MD. Acute myocardial infarction with cardiogenic shock during pregnancy: treatment with intra-aortic
balloon counterpulsation. Crit Care Med. 1990; 18:888-9.
21. Liao JK, Cockrill BA, Yurchak PM. Acute myocardial infarction after ergonovine administration for uterine bleeding. Am J
Cardiol. 1991; 68:823-4.
22. Frenkel Y, Etchin A, Barkai G, Reisin L, Mashiach S, Batler A. Myocardial infarction during pregnancy: a case report.
Cardiology. 1991; 78:363-8.
23. Ottman EH, Gall SA. Myocardial infarction in the third trimester of pregnancy secondary to an aortic valve thrombus. Obstet
Gynecol. 1993; 81(5 Pt 2):804-5.
24. Liu SS, Forrester RM, Murphy GS, Chen K, Glassenberg R. Anaesthetic management of a parturient with myocardial
infarction related to cocaine use. Can J Anaesth. 1992; 39:858-61.
25. Saxena R, Nolan TE, von Dohlen T, Houghton JL. Postpartum myocardial infarction treated by balloon coronary
angioplasty. Obstet Gynecol. 1992; 79(5 Pt 2):810-2.
26. Taylor GW, Moliterno DJ, Hillis LD. Peripartum myocardial infarction. Am Heart J. 1993; 126:1462-3.
27. Clark SL. Cardiac disease in pregnancy. Obstet Gynecol. 1987; 18:237-53.
28. Nolan TE, Hankins GD. Myocardial infarction in pregnancy. Clin Obstet Gynecol. 1989; 32:68-75.
29. Beary JF, Summer WR, Bulkley BH. Postpartum acute myocardial infarction: a rare occurrence of uncertain etiology. Am J
Cardiol. 1979; 43:158-61.
30. Aglio LS, Johnson MD. Anaesthetic management of myocardial infarction in a parturient. Br J Anaesth. 1990; 65:258-61.
31. Shaver PJ, Carrig TF, Baker WP. Postpartum coronary artery dissection. Br Heart J. 1978; 40:83-6.
32. Sasse L, Wagner R, Murray FE. Transmural myocardial infarction during pregnancy. Am J Cardiol. 1975; 35:448-52.
33. Taylor GJ, Cohen B. Ergonovine-induced coronary artery spasm and myocardial infarction after normal delivery. Obstet
Gynecol. 1985; 66:821-2.
34. Curry JJ, Quintana FJ. Myocardial infarction with ventricular fibrillation during pregnancy treated by direct current
defibrillation with fetal survival. Chest. 1970; 58:82-4.
35. Samra D, Samra Y, Hertz M, Maier M. Acute myocardial infarction in pregnancy and puerperium. Cardiology. 1989; 76:45560.
36. Yla-Outinen A, Lyrenas S, Lantz P, Langhoff-Roos J. Myocardial infarction in pregnancy. A case report and review of the
literature. Ups J Med Sci. 1989; 94:287-90.
37. Bornstein A, Dalal P, Tischler J, Novack S, Michaelson S. Acute myocardial infarction in a thirty-six year old postpartum
female. Angiology. 1984; 35:591-4.
38. Wittry MD, Zimmerman TJ, Janosik DL, Williams GA. Postpartum myocardial infarction in a patient with intermittent
ventricular preexcitation. Am Heart J. 1989; 117:191-4.
39. Sala DJ. Myocardial infarction. NAACOGS Clin Issu Perinat Womens Health Nurs. 1992; 3:443-53.
40. Bembridge M, Lyons G. Myocardial infarction in the third trimester of pregnancy. Anaesthesia. 1988; 43:202-4.
41. Parry G, Goudevenos J, Williams DO. Coronary thrombosis postpartum in a young woman with Still's disease. Clin Cardiol.
1992; 15:305-7.
42. Sanchez-Ramos L, Chami YG, Bass TA, DelValle GO, Adair CD. Myocardial infarction during pregnancy: management with
transluminal coronary angioplasty and metallic intracoronary stents. Am J Obstet Gynecol. 1994; 171:1392-3.
43. Hutchison SJ, Holden RJ, Lorimer AR. Myocardial infarction in pregnancy. Scott Med J. 1985; 30:116-8.
44. Brown A. Myocardial infarction associated with pregnancy. N Engl J Med. 1960; 23:1163-5.
45. Jewett JF. Committee on maternal welfare. Cholecystitis, cholelithiasis and coronary occlusion. N Engl J Med. 1957; 256:5745.
46. Canning BS, Green AT, Mulcahy R. Coronary heart disease in the puerperium. A case report. J Obstet Gynaecol Br
Commonw. 1969; 76:1018-20.
47. Husaini MH. Myocardial infarction during pregnancy: report of two cases with a review of the literature. Postgrad Med J. 1971;
47:660-5.
48. Hughes TB. Myocardial infarction and rheumatic heart disease in pregnancy. Case report. Br J Obstet Gynaecol. 1975;
82:505-7.
49. Sperry KL. Myocardial infarction in pregnancy. J Forensic Sci. 1987; 32:1464-70.
50. Watson H, Emslie-Smith D, Herring J. Myocardial infarction during pregnancy and puerperium. Lancet. 1960; 2:523-4.
51. McKeon VA, Perrin KO. The pregnant woman with a myocardial infarction: nursing diagnosis. Dimens Crit Care Nurs. 1989;
8:92-100.
52. Asuncion CM, Hyun J. Dissecting intramural hematoma of the coronary artery in pregnancy and the puerperium. Obstet
Gynecol. 1972; 40:202-10.
53. Ginz B. Myocardial infarction in pregnancy. J Obstet Gynaecol Br Commonw. 1970; 77:610-5.
54. Shapira E, Rosen RJ, Lederman B, Carey RJ. Myocardial infarction in the third trimester of pregnancy. JAMA. 1961;
179:966-7.
55. Brock HJ, Russell NG, Randall CR. Myocardial infarction in pregnancy. Report of a case with normal spontaneous delivery
seven months later. JAMA. 1953; 152:1030-1.
56. Goldberger E, Pokress MJ. Spontaneous delivery in a woman with myocardial infarction. N Y State J Med. 1950; 50:95-6.
57. Stokes IM, Evans J, Stone M. Myocardial infarction and cardiac arrest in the second trimester followed by assisted vaginal
delivery under epidural analgesia at 38 weeks gestation. Case report. Br J Obstet Gynaecol. 1984; 91:197-8.
58. Antonius NA, Izzo PA, Hayes GW, Walsh CR. Myocardial infarction in pregnancy. Am Heart J. 1955; 49:83-8.
59. White PD, Glendy E, Gustapson P. Myocardial infarction complicating pregnancy in a young woman. JAMA. 1937; 109:8634.
60. Fletcher E, Knox EW, Morton P. Acute myocardial infarction in pregnancy. Br Med J. 1967; 3:586-8.
61. Myers RF, Sharpe VJ. Acute myocardial infarction occurring during pregnancy. Can Med Assoc J. 1957; 76:754-8.
62. Mendelson CL. Coronary artery disease in pregnancy. Am J Obstet Gynecol. 1952; 63:381-91.
63. Reis RA, Frankenthal LE Jr. Labor in the cardiac patient. Am J Obstet Gynecol. 1935; 29:44-52.
64. Bruschke AV, Bruyneel KJ, Bloch A, van Herpen G. Acute myocardial infarction without obstructive coronary artery disease
demonstrated by selective cinearteriography. Br Heart J. 1971; 33:585-94.
65. Van Enk A, Visschers G, Jansen W, Satius van Eps LW. Maternal death due to sickle cell chronic lung disease. Br J Obstet
Gynaecol. 1992; 99:162-3.[Medline]
66. Sheikh AU, Harper MA. Myocardial infarction during pregnancy: management and outcome of two pregnancies. Am J Obstet
Gynecol. 1993; 169(2 Pt 1):279-84.
67. Freedman JR. Coronary occlusion with myocardial infarction in a puerperal patient. Am J Obstet Gynecol. 1956; 71:1106-10.
68. Vasicka AI, Lin TJ. Fatal coronary artery disease during the early postpartum period. Am J Obstet Gynecol. 1959; 77:899904.
69. Naden RS, Johnson HF, Murray EN. Myocardial infarction during pregnancy. JAMA. 1961; 178:659-61.
70. Forssell J, Brunila T. Cardiac infarction in pregnancy. Acta Med Scand. 1957; 157:387-97.
71. Verkaaik AP, Visser W, Deckers JW, Lotgering FK. Multiple coronary artery dissections in a woman at term. Br J Anaesth.
1993; 71:301-2.
72. Chant GN. Coronary anatomy in postpartum acute myocardial infarction. Am J Cardiol. 1980; 45:912.
73. Urdan BE, Madden WJ. Pregnancy complicated by myocardial infarction. Obstet Gynecol. 1959; 14:378-80.
74. Siegler AM, Hoffman J, Bloom O. Myocardial infarction complicating pregnancy. Obstet Gynecol. 1956; 7:306-11.
75. Glancy DL, Marcus ML, Epstein SE. Myocardial infarction in young women with normal coronary arteriograms. Circulation.
1971; 44:495-502.
76. Lamb MA. Myocardial infarction during pregnancy: a team challenge. Heart Lung. 1987; 16(6 Pt 1):658-61.
77. Listo M, Bjorkenheim G. Myocardial infarction during delivery. Acta Obstet Gynecol Scand. 1966; 45:268-78.
78. Duke M. Pregnancy, myocardial infarction and normal coronary arteries. A case study and long term follow-up. Conn Med.
1982; 46:626-8.
79. Henion WA, Hilal A, Matthew PK, Lazarus AR, Cohen J. Postpartum myocardial infarction. Associated with normal coronary
arteries. N Y State J Med. 1982; 82:57-62.
80. Menegakis NE, Amstey MS. Case report of myocardial infarction in labor. Am J Obstet Gynecol. 1991; 165(5 Pt 1):1383-4.
81. Adler JJ, Barrash MJ, Lash SR. Myocardial infarction during pregnancy. IMJ Ill Med J. 1968; 134:143-6.
82. Bechtel JT, Lanford WS, Mangone EK. Myocardial infarction associated with twin pregnancy. Report of a case and review of
literature. J Fla Med Assoc. 1963; 49:658-61.
83. Levine EL, Lanning RJ. Myocardial infarction immediately following delivery. Mo Med. 1956; 53:967.
84. Lewis JF. Myocardial infarction during pregnancy: with associated myocardial Bacteroides abscess. South Med J. 1973;
66:379-81.
85. Roberts AD, Low RA, Rae AP, Hillis WS. Left ventricular aneurysm complicating acute myocardial infarction occurring during
pregnancy. Case report. Br J Obstet Gynaecol. 1983; 90:969-70.
86. Pfaffenschlager F. Myokardinfarkt und schwangerschaft. Wien Klin Wochenschr. 1964; 76:297-9.
87. Pantev I, Piperkov T. [On myocardial infarct in pregnancy.] Akush Ginekol (Sofia). 1968; 7:158-61.
88. Ahronheim JH. Isolated coronary periarteritis: report of a case of unexpected death in a young pregnant woman. Am J
Cardiol. 1977; 40:287-90.
89. Magner D. Coronary occlusion in labour. J Obstet Gynaecol Br Commonw. 1961; 68:128-9.
90. Wells AL. Dissecting aneurysm of coronary artery in the puerperium. J Pathol Bacteriol. 1960; 79:404-5.
91. Palomino SJ. Dissecting intramural hematoma of left coronary artery in the puerperium: a case report and survey of the
literature. Am J Clin Pathol. 1969; 51:119-25.
92. Di Maio VJ, Di Maio DJ. Postpartum dissecting coronary aneurysm. N Y State J Med. 1971; 71:767-9.[Medline]
93. Jessurun CR, Adam K, Moise KJ Jr, Wilansky S. Pheochromocytoma-induced myocardial infarction in pregnancy. A case
report and literature review. Tex Heart Inst J. 1993; 20:120-2.
94. Jensen SE, Simonsen EE, Thayssen P. Acute myocardial infarction during early pregnancy. J Intern Med. 1994; 235:487-8.
95. McHugh MJ, Taubman MR. Postpartum myocardial infarction: a rehabilitation challenge. J Cardiovasc Nurs. 1990; 4:57-63.
96. Efstratiou A, Singh B. Combined spontaneous postpartum coronary artery dissection and pulmonary embolism with survival.
Cathet Cardiovasc Diagn. 1994; 31:29-33.
97. Emori T, Goto Y, Maeda T, Chiba Y, Haze K. Multiple coronary artery dissections diagnosed in vivo in a pregnant woman.
Chest. 1993; 104:289-90.
98. Jacobs M, Moress EJ. Myocardial infarction complicating pregnancy. Journal of Newark Beth Israel Hospital. 1961; 12:21621.
99. Maternal health in Ohio. Topic this month: maternal deaths involving cardiac disease. Ohio State Medical Journal. 1958;
54:187-8.
100. Etienne Y, Jobic Y, Houel JF, Barra JA, Boschat J, Meunier M, et al. Papillary fibroelastoma of the aortic valve with
myocardial infarction: echocardiographic diagnosis and surgical excision. Am Heart J. 1994; 127:443-5.
101. Phillips E. Myocardial infarction in pregnancy. JAMA. 1962; 181:63.
102. Dement'eva MP, Liakhov NT, Timoshek ZK, Maidan GP. [Case of myocardial infarct in a pregnant woman.] Klin Med
(Mosk). 1975; 53:141-3.
103. Krawczuk A, Jakowiki J. Two cases of myocardial infarction in the course of labour. Ginekol Pol. 1965; 36:1183-4.
104. Bielak J, Krystosik J. [Myocardial infarction in a 24-year-old pregnant woman.] Wiad Lek. 1973; 26:951-4.
105. Bedford JR. Myocardial infarction in pregnancy. Obstet Gynecol. 1964; 71:459-60.
106. Capra Marzani P, Navazzotti R. [Myocardial infarct in pregnancy. Description of a case.] Minerva Med. 1969; 60:140711.[Medline]
107. Pardo J, Gonzalez B, Novoa O, Pumarino R, Oppliger E, Godoy D. [Acute post-partum infarct of the myocardium
secondary to a spontaneous dissection of the coronary artery.] Rev Med Chil. 1990; 118:300-5.
108. Perucca E, Cazenave H, Zarate H, Gutierrez I, Barrera C, Fuenzalida JP. [Myocardial infarction and pregnancy.] Rev Chil
Obstet Ginecol. 1991; 56:210-2.
109. Rekosz J, Buczek J, Puchalska-Krotki H, Kapitan-Malinowska B. [Cardiac rupture and tamponade in a pregnant woman
with acute myocardial infarction.] Kardiol Pol. 1992; 36:224-6.
110. Reece EA, Assimakopoulos A. Coronary artery disease. In: Gleicher N, ed. Principles and Practice of Medical Therapy in
Pregnancy. 2d ed. Norwalk, CT: Appleton & Lange; 1992:817-22.
111. Gant NF, Daley GL, Chand S, Whalley PJ, MacDonald PC. A study of angiotensin II pressor response throughout
primigravid pregnancy. J Clin Invest. 1973; 52:2682-9.
112. Nisell H, Hjemdahl P, Linde B. Cardiovascular responses to circulating catecholamines in normal pregnancy and in
pregnancy-induced hypertension. Clin Physiol. 1985; 5:479-93.
113. Roberts JM, Taylor RN, Musci TJ, Rodgers GM, Hubel CA, McLaughlin MK. Preeclampsia: an endothelial cell disorder.
Am J Obstet Gynecol. 1989; 161:1200-4.
114. Koh CL, Viegas OA, Yuen R, Chua SE, Ng BL, Ratnam SS. Plasminogen activators and inhibitors in normal late
pregnancy, postpartum and in the postnatal period. Int J Gynaecol Obstet. 1992; 38:9-18.
115. Fletcher AP, Alkjaersig NK, Burstein R. The influence of pregnancy upon blood coagulation and plasma fibrinolytic
enzyme function. Am J Obstet Gynecol. 1979; 134:743-51.
116. Gore M, Eldon S, Trofatter KF, Soong SJ, Pizzo SV. Pregnancy-induced changes in the fibrinolytic balance: evidence for
defective release of tissue plasminogen activator and increased levels of the fast-acting tissue plasminogen activator inhibitor. Am
J Obstet Gynecol. 1987; 156:674-80.
117. Mackinnon S, Walker ID, Davidson JF, Walker JJ. Plasma fibrinolysis during and after normal childbirth. Br J Haematol.
1987; 65:339-42.
118. McGehee W. Anticoagulation in pregnancy. In: Elkayam U, Gleicher N, eds. Cardiac Problems in Pregnancy: Diagnosis and
Management of Maternal and Fetal Disease. 2d ed. New York: Liss; 1990:397.
119. Yoshimura T, Ito M, Nakamura T, Okamura H. The influence of labor on thrombotic and fibrinolytic systems. Eur J Obstet
Gynecol Reprod Biol. 1992; 44:195-9.
120. Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during
pregnancy. Blood. 1986; 68:881-5.
121. Davis RB, Leuschen MP, Boyd D, Goodlin RC. Evaluation of platelet function in pregnancy. Comparative studies in nonsmokers and smokers. Thromb Res. 1987; 46:175-86.
122. Elkayam U, Rose J, Jamison M. Vascular aneurysms and dissections during pregnancy. In: Elkayam U, Gleicher N, eds.
Cardiac Problems in Pregnancy: Diagnosis and Management of Maternal and Fetal Disease. 2d ed. New York: Liss; 1990:215.
123. Smith JC. Dissecting aneurysm of coronary arteries. Arch Pathol Lab Med 1975; 99:117-21.
124. Menalo-Estrella P, Barker AE. Histopathologic findings in human aortic media associated with pregnancy. Arch Pathol Lab
Med 1967; 83:336-41.
125. Bonnet J, Aumailley M, Thomas D, Grosgogeat Y, Broustet JP, Bricaud H. Spontaneous coronary artery dissection:
case report and evidence for a defect in collagen metabolism. Eur Heart J 1986; 7:904-9.
126. Elkayam U, Gleicher N. Hemodynamics and cardiac function during normal pregnancy and the puerperium. In: Elkayam U,
Gleicher N, eds. Cardiac Problems in Pregnancy. 2d ed. New York: Liss; 1990:5-24.
127. Elkayam U, Gleicher N. Changes in cardiac findings during normal pregnancy. In: Elkayam U, Gleicher N, eds. Cardiac
Problems in Pregnancy. 2d ed. New York: Liss; 1990:31-38.
128. Palmer CM, Norris MC, Giudici MC, Leighton BL, DeSimone CA. Incidence of electrocardiographic changes during
cesarean delivery under regional anesthesia. Anesth Analg. 1990; 70:36-43.
129. McLintic AJ, Pringle SD, Lilley S, Houston AB, Thorburn J. Electrocardiographic changes during cesarean section under
regional anesthesia. Anesth Analg. 1992; 74:51-6.
130. Elkayam U. Pregnancy and cardiovascular disease. In: Braunwald E, ed. Heart Disease: A Textbook of Cardiovascular
Medicine. 4th ed. Philadelphia: WB Saunders; 1992:1790-809.
131. Page RL. Treatment of arrhythmias during pregnancy. Am Heart J. 1996; 130:871-6.
132. Brent RL. The effect of embryonic and fetal exposure to x-ray, microwaves, and ultrasound: counseling the pregnant and
nonpregnant patient about these risks. Semin Oncol. 1989; 16:347-68.
133. Heinonen OP, Slone D, Shapiro S. Birth Defects and Drugs in Pregnancy. Littleton, MA: Publishing Sci; 1977:434.
134. American Academy of Pediatrics Committee on Drugs. The transfer of drugs and other chemicals into human milk.
Pediatrics. 1994; 93:137-50.
135. Turrentine MA, Braems G, Ramirez MM. Use of thrombolytics for the treatment of thromboembolic disease during
pregnancy. Obstet Gynecol Surv. 1995; 50:534-41.
136. Delclos GL, Davila F. Thrombolytic therapy for pulmonary embolism in pregnancy: a case report. Am J Obstet Gynecol.
1986; 155:375-6.
137. Ludwig H, Genz HJ. Thrombolytic treatment during pregnancy [Abstract]. Thromb Haemost. 1981; 46:438.
138. Tissot H, Vergnes C, Rougier P, Bricaud H, Dallay D. [Fibrinolytic treatment with urokinase and streptokinase for recurrent
thrombosis in two valve prostheses for the aortic and mitral valves during pregnancy.] J Gynecol Obstet Biol Reprod (Paris). 1991;
20:1093-6.
139. Pfeifer GW. The use of thrombolytic therapy in obstetrics and gynaecology. Australas Ann Med. 1970; 19(Suppl 1):28-31.
140. Amias AG. Streptokinase, cerebrovascular disease—and triplets [Letter]. Br Med J. 1977; 1:1414-5.
141. Hall RJ, Young C, Sutton GC, Campbell S. Treatment of acute massive pulmonary embolism by streptokinase during
labour and delivery. Br Med J. 1972; 4:647-9.
142. Fagher B, Ahlgren M, Astedt B. Acute massive pulmonary embolism treated with streptokinase during labor and the early
puerperium. Acta Obstet Gynecol Scand. 1990; 69:659-61.
143. Ramamurthy S, Talwar KK, Saxena A, Juneja R, Takkar D. Prosthetic mitral valve thrombosis in pregnancy successfully
treated with streptokinase. Am Heart J. 1994; 127:446-8.
144. Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve prostheses. Br Heart J. 1994; 71:196-201.
145. Flossdorf T, Breulmann M, Hopf HB. Successful treatment of massive pulmonary embolism with recombinant tissue type
plasminogen activator (rt-PA) in a pregnant woman with intact gravidity and preterm labour. Intensive Care Med. 1990; 16:454-6.
146. Baudo F, Caimi TM, Redaelli R, Nosari AM, Mauri M, Leonardi G, et al. Emergency treatment with recombinant tissue
plasminogen activator of pulmonary embolism in a pregnant woman with antithrombin III deficiency. Am J Obstet Gynecol. 1990;
163(4 Pt 1):1274-5.
147. Barclay GR, Allen K, Pennington CR. Tissue plasminogen activator in the treatment of superior vena caval thrombosis
associated with parenteral nutrition. Postgrad Med J. 1990; 66:398-400.
148. Witchitz S, Veyrat C, Moisson P, Scheinman N, Rozenstajn L. Fibrinolytic treatment of thrombus on prosthetic heart
valves. Br Heart J. 1980; 44:545-54.
149. Shepard TH. Catalog of Teratogenic Agents. 6th ed. Baltimore: Johns Hopkins Univ Pr; 1989:655.
150. McTaggart DR, Ingram TG. Massive pulmonary embolism during pregnancy treated with streptokinase. Med J Aust. 1977;
1:18-20.
151. Ginsberg JS, Hirsh J. Use of antithrombotic agents during pregnancy. Chest. 1995; 108(4 Suppl):305S-311S.
152. Anderson DR, Ginsberg JS, Burrows R, Brill-Edwards P. Subcutaneous heparin therapy during pregnancy: a need for
concern at the time of delivery. Thromb Haemost. 1991; 65:248-50.
153. Stuart MJ, Gross SJ, Elrad H, Graeber JE. Effects of acetylsalicylic-acid ingestion on maternal and neonatal hemostasis. N
Engl J Med 1982; 307:909-12.
154. Zierler S, Rothman KJ. Congenital heart disease in relation to maternal use of Bendectin and other drugs in early
pregnancy. N Engl J Med. 1985; 313:347-52.
155. Viinikka L, Hartikainen-Sorri AL, Lumme R, Hiilesmaa V, Ylikorkala O. Low dose aspirin in hypertensive pregnant
women: effect on pregnancy outcome and prostacyclin-thromboxane balance in mother and newborn. Br J Obstet Gynaecol.
1993; 100:809-15.
156. CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant
women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group. Lancet. 1994; 343:619-29.
157. Cotton DB, Longmire S, Jones MM, Dorman KF, Tessem J, Joyce TH 3d. Cardiovascular alterations in severe
pregnancy-induced hypertension: effects of intravenous nitroglycerin coupled with blood volume expansion. Am J Obstet Gynecol.
1986; 154:1053-9.
158. Shalev Y, Ben-Hur H, Hagay Z, Blickstein I, Epstein M, Ayzenberg O, et al. Successful delivery following myocardial
ischemia during the second trimester of pregnancy. Clin Cardiol. 1993; 16:754-6.
159. Lees C, Campbell S, Jauniaux E, Brown R, Ramsay B, Gibb D, et al. Arrest of preterm labour and prolongation of
gestation with glyceryl trinitrate, a nitric oxide donor. Lancet. 1994; 343:1325-6.
160. Frishman W, Chesner M. Use of ß-adrenergic blocking agents in pregnancy. In: Elkayam U, Gleicher N, eds. Cardiac
Problems in Pregnancy: Diagnosis and Management of Maternal and Fetal Disease. 2d ed. New York: Liss; 1990:351-9.
161. Childress CH, Katz VL. Nifedipine and its indications in obstetrics and gynecology. Obstet Gynecol. 1994; 83:616-24.
162. Widerhorn J, Shotan A, Widerhorn AL, Elkayam U. Antiarrhythmic. In: Lee RV, Garner PR, Barron WM, Coustan DR, eds.
Current Obstet Med. 1995; 3:95-116.
163. Diltiazem. In: Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and
Neonatal Risk. 4th ed. Baltimore: Williams & Wilkins; 1994:287-8.
164. Shechter M, Hod H, Chouraqui P, Kaplinsky E, Rabinowitz B. Magnesium therapy in acute myocardial infarction when
patients are not candidates for thrombolytic therapy. Am J Cardiol. 1995; 75:321-3.
165. Magnesium sulfate. In: Briggs GG, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal
and Neonatal Risk. 4th ed. Baltimore: Williams & Wilkins; 1994:513-8.
166. Brady JP, Williams HC. Magnesium intoxication in a premature infant. Pediatrics. 1967; 40:100-3.
167. Widerhorn J, Widerhorn AL, Elkayam U. Cardiovascular pharmacotherapy in pregnancy and lactation. In: Gleicher N, ed.
Principles and Practice of Medical Therapy in Pregnancy. 2d ed. Norwalk, CT: Appleton & Lange; 1992:767-83.
168. Clark RB, Brunner JA 3d. Dopamine for the treatment of spinal hypotension during cesarean section. Anesthesiology. 1980;
53:514-7.
169. Fishburne JI Jr, Dormer KJ, Payne GG, Gill PS, Ashrafzadeh AR, Rossavik IK. Effects of amrinone and dopamine on uterine
blood flow and vascular responses in the gravid baboon. Am J Obstet Gynecol. 1988; 158:829-37.[Medline]
170. Kirshon B, Lee W, Mauer MB, Cotton DB. Effects of low-dose dopamine therapy in the oliguric patient with preeclampsia.
Am J Obstet Gynecol. 1988; 159:604-7.
171. Waring PH, Shaw DB, Brumfield CG. Anesthetic management of a parturient with Osler-Weber-Rendu syndrome and
rheumatic heart disease. Anesth Analg. 1990; 71:96-9.
172. Shotan A, Widerhorn J, Hurst A, Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy:
experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med. 1994; 96:451-6.
173. Gregg AR, Tomich PG. Mexilitene use in pregnancy. J Perinatol. 1988; 8:33-5.
174. Perry JC, Ayres NA, Carpenter RJ Jr. Fetal supraventricular tachycardia treated with flecainide acetate. J Pediatr. 1991;
118:303-5.
175. Wagner X, Jouglard J, Moulin M, Miller AM, Petitjean J, Pisapia A. Coadministration of flecainide acetate and sotalol
during pregnancy: lack of teratogenic effects, passage across the placenta, and excretion in human breast milk. Am Heart J. 1990;
119(3 Pt 1):700-2.
176. Widerhorn J, Bhandari AK, Bughi S, Rahimtoola SH, Elkayam U. Fetal and neonatal adverse effects profile of
amiodarone treatment during pregnancy. Am Heart J. 1991; 122(4 Pt 1):1162-6.
177. Elkayam U, Goodwin TM. Adenosine therapy for supraventricular tachycardia during pregnancy. Am J Cardiol. 1995;
75:521-3.
178. Jaffe R, Gruber A, Fejgin M, Altaras M, Ben-Aderet N. Pregnancy with an artificial pacemaker. Obstet Gynecol Surv. 1987;
42:137-9.
179. Zoll PM, Zoll RH, Falk RH, Clinton JE, Eitel DR, Antman EM. External noninvasive temporary cardiac pacing: clinical trials.
Circulation. 1985; 71:937-44.
180. Majdan JF, Walinsky P, Cowchock SF, Wapner RJ, Plzak L Jr. Coronary artery bypass surgery during pregnancy. Am J
Cardiol. 1983; 52:1145-6.
181. Gazzaniga AB. Cardiac surgery during pregnancy. In: Elkayam U, Gleicher N, eds. Cardiac Problems in Pregnancy:
Diagnosis and Management of Maternal and Fetal Disease. 2d ed. New York: Liss; 1990:264.
182. Troiano NH. Cardiopulmonary resuscitation of the pregnant woman. J Perinat Neonatal Nurs. 1989; 3:1-13.
183. Marx GF. Cardiopulmonary resuscitation of late-pregnant women [Letter]. Anesthesiology. 1982; 56:156.
184. Goodwin AP. The human wedge. A manoeuvre to relieve aortocaval compression during resuscitation in late pregnancy.
Anaesthesia. 1992; 47:433-4.
185. DePace NL, Betesh JS, Kotler MN. ‘Postmortem’ cesarean section with recovery of both mother and offspring. JAMA. 1982;
248:971-3.
186. Lee RV, Rodgers BD, White LM, Harvey RC. Cardiopulmonary resuscitation of pregnant women. Am J Med. 1986; 81:3118.
187. Katz VL, Dotters DJ, Droegemueller W. Perimortem cesarean delivery. Obstet Gynecol. 1986; 68:571-6.
188. Dillon WP, Lee RV, Tronolone MJ, Buckwald S, Foote RJ. Life support and maternal death during pregnancy. JAMA.
1982; 248:1089-91.
189. Hill LM, Parker D, O'Neill BP. Management of maternal vegetative state during pregnancy. Mayo Clinic Proc. 1985; 60:46972.
190. Strong TH Jr, Lowe RA. Perimortem cesarean section. Am J Emerg Med. 1989; 7:489-94.[Medline]
191. Karlsson K. The influence of hypoxia on uterine and maternal placental blood flow, and the effect of
blockade. J Perinat Med. 1974; 2:176-84.
-adrenergic
192. Chestnut DH, Zlatnik FJ, Pitkin RM, Varner MW. Pregnancy in a patient with a history of myocardial infarction and
coronary artery bypass grafting. Am J Obstet Gynecol. 1986; 155:372-3.
193. Carpenter MW, Sady SP, Hoegsberg B, Sady MA, Haydon B, Cullilnane EM, et al. Fetal heart rate response to maternal
exertion. JAMA. 1988; 259:3006-9.
194. Frenkel Y, Barkai G, Reisin L, Rath S, Mashiach S, Battler A. Pregnancy after myocardial infarction: are we playing safe?
Obstet Gynecol. 1991; 77:822-5.